Sanofi announced a strategic equity investment and research collaboration with InduPro Therapeutics, a biotechnology company focused on bispecific antibodies for autoimmune and inflammatory disorders. The deal grants Sanofi a right of first negotiation for InduPro’s preclinical PD‑1 agonist program and includes undisclosed equity funding to support joint preclinical and IND‑enabling studies.
The partnership is designed to accelerate the development of a novel bispecific PD‑1 agonist that could address unmet needs in autoimmune diseases such as rheumatoid arthritis and systemic lupus erythematosus. By combining Sanofi’s global commercialization expertise with InduPro’s proximity‑based discovery platform, the collaboration aims to bring the candidate into clinical testing more rapidly than either company could achieve alone.
The investment expands Sanofi’s immunology pipeline, adding a first‑in‑class therapeutic approach that complements its existing Dupixent and other biologic assets. Sanofi’s leadership emphasized that the collaboration fits into its broader strategy to diversify revenue beyond flagship products and to invest in high‑potential early‑stage biologics.
InduPro’s proprietary proximity labeling technology enables the identification of co‑target pairs with high selectivity for disease biology, giving the partnership a unique scientific advantage. While the financial terms of the deal remain undisclosed, the collaboration signals Sanofi’s commitment to exploring cutting‑edge science in the immunology space.
The partnership also reflects the growing interest in PD‑1 agonists for autoimmune conditions, a therapeutic area that has attracted attention from other companies such as Eli Lilly. By securing a first‑in‑class bispecific PD‑1 agonist, Sanofi positions itself to compete in this emerging landscape and to broaden its portfolio of innovative therapies.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.